Compare Abbott Laboratories (ABT) vs Emerson Electric Co. (EMR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Emerson Electric Co. — how do they compare? Abbott Laboratories trades at $95.39 (market cap $166.94B), while Emerson Electric Co. trades at $135.57 (market cap $77.24B). The key difference: Abbott Laboratories is far larger — about 2.2× Emerson Electric Co.'s market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | EMR | |
|---|---|---|
Market Cap | $166.94B | $77.24B |
Sector | Health | Industrials |
52-Week High | $136.62 | $161.69 |
52-Week Low | $82.57 | $123.30 |
Enterprise Value | $193.69B | $89.51B |
Dividend Yield | 2.63% | 1.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Emerson Electric (EMR) trades at $137.91, down 0.82% on the day, with a neutral technical signal and mixed earnings history. The company maintains solid profitability with a 52.67% gross margin and 13.35% net margin, though ROE is modest at 3.05%. Recent news highlights collaboration with Aramco on corrosion R&D and positive momentum in its Intelligent Devices segment, while cash flow trends show volatility with a net outflow of $2.04B in 2025.
The outlook is cautiously optimistic, supported by a majority analyst buy rating and a $157.60 consensus price target implying 14% upside. Key risks include fluctuating cash flows, elevated debt levels, and competitive pressures in the industrial automation sector. Earnings growth and segment execution remain critical for sustained stock appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →
